View Clinical Trial (Medical Research Study)
Craving, Binge Eating and Obesity - NCT00414167-06520(Clinical Trial 159091)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
New Haven |
|
State:
|
|
CT |
| Zip Code: |
|
06520 |
| Conditions: |
|
Binge Eating Disorder - Obesity |
| Purpose: |
|
This research study is designed to look at the effectiveness of bupropion for reducing binge
eating in overweight persons with binge eating problems. Participants in the study will
receive either bupropion or placebo ("sugar" pill, inactive medication) as an outpatient for
eight weeks. In addition, participants will be given the option to receive 8 weeks of free
behavioral weight loss treatment. This treatment, known to be effective for reducing binge
eating and helping people lose weight, will be administered following the medication phase
and at no cost.
It is expected that compared to placebo, bupropion will produce greater reductions in binge
eating.
|
| Study summary: |
|
The proposed study is an 8-week randomized placebo-controlled trial to test the efficacy of
bupropion in treating overweight women with binge eating disorder (BED). Bupropion is an
antidepressant that has demonstrated efficacy in smoking cessation and some efficacy in
obesity treatment. Since cravings and depressed mood are hypothesized to contribute to binge
eating episodes, bupropion is a promising psychopharmacological agent in treating binge
eating and reducing weight. It is hypothesized that compared to placebo, bupropion will
produce significantly greater reductions in the frequency of binge eating. Secondary goals
are to explore interrelationships between treatment and changes in cravings, frequency of
binge episodes, emotional eating, and weight loss. Following the medication phase of the
trial, all patients will be offered 8 weeks of behavioral weight loss treatment administered
by doctoral-level psychologists specializing in eating disorders and weight management. |
| Criteria: |
|
Inclusion Criteria:
- BMI 25-50
- Able to travel to clinical site (New Haven, CT) for bi-weekly visits.
Exclusion Criteria:
- Predisposition to seizures
- History of anorexia or bulimia nervosa
- Current Type I or Type II diabetes mellitus |
|
|
|
| Study is available at: |
|
Yale University School of Medicine
New Haven, CT 06520
United States
Primary Contact:
Abbe Boeka, PhD
Email: abbe.boeka@yale.edu
Phone: 203-785-6040 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 21, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|